Apr 3, 2022
Liraglutide May Ease Peripheral Artery Disease in T2D
TOPLINE: In people with type 2 diabetes (T2D) and peripheral artery disease (PAD), liraglutide significantly increased peripheral perfusion over 6 months compared with conventional treatment of cardiovascular risk factors. METHODOLOGY: An open-label randomised clinical trial conducted between February 1, 2021, and June 30, 2022, with a final follow-up on December 30, 2022, at a single